SI
DCPH

Sofinnova Investments’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Sofinnova Investments’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-214,604
Closed -$5.02M – 84
2019
Q1 		$4.98M Sell
214,604
-50,871
-19% -$1.33M 0.48% 39
2018
Q4 		$5.57M Buy
+265,475
New +$6.53M 0.69% 29

Other funds holding DCPH

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Sofinnova Investments's DCPH Position: Q2 2019 in Review

Sofinnova Investments sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q2 2019, closing a stake of 214,604 shares — an estimated $5.02M sold.

Sofinnova Investments first reported a position in DCPH in Q4 2018 and held it in 2 quarters. The position peaked at $5.57M in Q4 2018. 85 funds tracked by Wall St. Rank hold DCPH as of Q2 2019.

  • Sofinnova Investments reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q2 2019 after selling out during the quarter.
  • Sofinnova Investments sold 214,604 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q2 2019, an estimated $5.02M.
  • Sofinnova Investments first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2018 and held it in 2 quarters.
  • Sofinnova Investments's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $5.57M in Q4 2018.
  • 85 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q2 2019.

Based on Sofinnova Investments's 13F filing for Q2 2019, filed 13 Aug 2019.